Status:
TERMINATED
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Lung Cancer
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to measure the ability of erlotinib to effectively treat recurrent lung cancer which carries an EGFR mutation lung cancer after prior treatment with erlotinib or gefitinib...
Eligibility Criteria
Inclusion
- A history of stage I-IIIB NSCLC
- Previously underdone definitive surgery or radiation
- Received prior adjuvant treatment or neoadjuvant with erlotinib or gefitinib for a total of at least 3 months at any time
- Stopped adjuvant erlotinib or neoadjuvant at least 2 months prior to date of first imaging demonstrating recurrence
- Pathologic evidence of recurrent lung cancer, confirmed at MSKCC EGFR sensitizing mutation (point mutation in exons 18 or 21, or deletion in exon 19) must be documented in the primary or recurrent tumor
- Tissue from their recurrent tumor must be submitted for EGFR mutation testing, and to evaluate for the presence of the T790M mutation (results do not need to have been reported to be eligible)
- Measurable disease by RECIST; if received prior irradiation, then must have a target lesion outside the irradiated field
- Signed informed consent
- Age \> or = to 21 years old
- Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped
Exclusion
- Prior progressive disease while receiving erlotinib or gefitinib therapy
- Patients with known pre-existing interstitial lung disease
- Total bilirubin greater than 1.8 mg/dl, excepting patients known to have Gilbert's syndrome
- AST or ALT greater than five times the upper limit of normal
- Pregnant or lactating women
- Medically unfit for erlotinib therapy as determined by treating oncologist
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01189435
Start Date
August 1 2010
End Date
January 1 2012
Last Update
November 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065